H.C. Wainwright reiterates Gain Therapeutics stock rating at buy

H.C. Wainwright has reaffirmed its Buy rating for Gain Therapeutics (NASDAQ:GANX) shares, maintaining a price target of $8.00. The stock is currently trading at $1.77, down 45% year-to-date, but analysts believe the company is undervalued at its current price. Gain Therapeutics received FDA authorization for its Investigational New Drug application for lead candidate GT-02287, which will initiate a Phase 2 clinical assessment for Parkinson's disease in the U.S. The company's Phase 1 trials in Australia showed promising biomarker and clinical evidence, along with favorable safety and tolerability.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.